Blog: MS news

UK MS Register request people with MS to complete a questionnaire about Coronavirus

2 April 2020

Source MS Register: We understand that you might be feeling worried about the Coronavirus(COVID-19) and your MS. We have put this page together as an information resource, it will be updated with new information as appropriate.

BMSTC Update 27th March - Help is at hand

27 March 2020

Hello everyone! Well, who would have thought we would be where we are right now!

BMSTC will be closing for all services from Monday 16th March

12 March 2020

Following the latest updates on coronavirus, the Management and Trustees have taken the difficult decision to close the Centre for all services from Monday 16th March. We hope this action will help to reduce the risk of infection, especially within our BMSTC community.

Coronavirus and MS

6 March 2020

Source Multiple Sclerosis International Federation: The coronavirus and MS – what you need to know

MS Patients Switching from Tysabri to Other Therapies May Risk Disease Activity

26 February 2020

Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have an increased risk of disease activity, though the risk is lower if the switch is limited to three months, a study found.

Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial Reports

26 February 2020

Source Multiple Sclerosis News Today: AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show.

Online Fatigue- management course

27 January 2020

Source MS Society: This online course will help you find ways to manage your MS fatigue and explain it to other people.

New guidance on MS Society grants

27 January 2020

Source MS Society: Our Health and Wellbeing grants are there to help you pay for items that will have a significant positive impact on your life.

Siponimod licensed for secondary progressive MS

24 January 2020

Source MS Society: This week the European Medicines Agency (EMA) granted a license for siponimod (brand name Mayzent) to treat adults with secondary progressive MS with active disease.